Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 2291 to 2300 of 2579 total matches.

Enfuvirtide (Fuzeon) for HIV infection

   
The Medical Letter on Drugs and Therapeutics • Jun 23, 2003  (Issue 1159)
weeks’ treatment were 1.70 log 10 copies/mL and 1.4 log 10 copies/mL with enfuvirtide and 0.76 log ...
Enfuvirtide (T-20; Fuzeon Trimeris/Roche), the first in a new class of HIV drugs known as fusion inhibitors, has received accelerated approval from the FDA for use with other antiretrovirals in adults and children with viral replication despite ongoing antiretroviral therapy. This review describes the mechanism of action and pharmacokinetics of the new drug, and outlines the results of the 2 clinical studies that led to its approval. Sections on adverse effects, development of resistance, and dosage and cost are also included. The review concludes with an overall assessment of the...
Med Lett Drugs Ther. 2003 Jun 23;45(1159):49-50 |  Show IntroductionHide Introduction

Folic Acid Supplementation to Prevent Neural Tube Defects

   
The Medical Letter on Drugs and Therapeutics • Mar 01, 2004  (Issue 1177)
Publication Vol. 46 (Issue 1177) March 1, 2004 EDITOR: Mark Abramowicz, M.D. DEPUTY EDITOR: Gianna Zuccotti ...
Many women of child-bearing age now take folic acid supplements of 400 ╡g per day to prevent neural tube defects in their offspring (Medical Letter 1998; 40:75). An FDA advisory committee has recommended development of a combination tablet containing an oral contraceptive and 400 ╡g of folic acid. A recent editorial in the New England Journal of Medicine suggested that folic acid doses should be higher (NJ Wald, N Engl J Med 2004; 350:101).
Med Lett Drugs Ther. 2004 Mar 1;46(1177):17-8 |  Show IntroductionHide Introduction

In Brief: Extended-Release Amoxicillin for Strep Throat

   
The Medical Letter on Drugs and Therapeutics • Mar 09, 2009  (Issue 1307)
in adolescents and adults has been penicillin V 250 mg taken three or four times a day. 1 Amoxicillin ...
The FDA has approved an extended-release formulation of amoxicillin (Moxatag – MiddleBrook) for once-daily treatment of pharyngitis or tonsillitis caused by Streptococcus pyogenes in adults and children ≥12 years old. Approval was based on an unpublished study that found once-daily treatment with Moxatag 775 mg for 10 days non-inferior to penicillin V 250 mg four times a day for 10 days in eradication of S. pyogenes.For decades, the drug of choice for oral treatment of streptococcal pharyngitis in adolescents and adults has been penicillin V 250 mg taken three or four times a day.1...
Med Lett Drugs Ther. 2009 Mar 9;51(1307):17 |  Show IntroductionHide Introduction

Drugs for MRSA with Reduced Susceptibility to Vancomycin

   
The Medical Letter on Drugs and Therapeutics • May 04, 2009  (Issue 1311)
article on vancomycin dosing and monitoring 1 briefly mentioned use of an alternative antibiotic ...
The recent Medical Letter article on vancomycin dosing and monitoring briefly mentioned use of an alternative antibiotic for treatment of methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to vancomycin. Some readers have asked for more information on this subject.

Click here to view the free full article.
Med Lett Drugs Ther. 2009 May 4;51(1311):36 |  Show IntroductionHide Introduction

Colon Cleansing

   
The Medical Letter on Drugs and Therapeutics • May 18, 2009  (Issue 1312)
; as with all dietary supplements, their purity is suspect. 1 Oral colon cleansers are available as capsules ...
Web sites and blogs are advising patients that periodic "cleansing" of the colon is necessary to rid the body of toxins.
Med Lett Drugs Ther. 2009 May 18;51(1312):39-40 |  Show IntroductionHide Introduction

In Brief: Heat and Transdermal Fentanyl

   
The Medical Letter on Drugs and Therapeutics • Aug 10, 2009  (Issue 1318)
system for patients with chronic pain 1 but it has some drawbacks. One is that exposing the patch ...
Transdermal fentanyl (Duragesic, and others) offers a convenient delivery system for patients with chronic pain1 but it has some drawbacks. One is that exposing the patch to heat, either from an external source, increased exertion or possibly high fever, could increase release of the drug, which might lead to an overdose and fatal respiratory depression.2 A recent article in the NY Times about this problem may have aroused the concerns of some patients using the patches.3First approved for marketing by the FDA in 19914, transdermal fentanyl provides continuous delivery of the drug for about 3...
Med Lett Drugs Ther. 2009 Aug 10;51(1318):64 |  Show IntroductionHide Introduction

Perampanel (Fycompa) for Epilepsy

   
The Medical Letter on Drugs and Therapeutics • Feb 03, 2014  (Issue 1435)
Perampanel (Fycompa) for Epilepsy Table 1. Pharmacology Drug class Noncompetitive AMPA receptor antagonist ...
Perampanel (per am’ pa nel; Fycompa – Eisai), a first-in-class noncompetitive AMPA receptor antagonist, has been approved by the FDA for adjunctive treatment of partial-onset seizures in patients ≥12 years old. New drugs for epilepsy are often initially approved by the FDA as adjunctive treatment for partial seizures.
Med Lett Drugs Ther. 2014 Feb 3;56(1435):9-10 |  Show IntroductionHide Introduction

Cytomegalovirus Immune Globulin

   
The Medical Letter on Drugs and Therapeutics • Oct 21, 1988  (Issue 777)
resulting from any error, inaccuracy or omission. Copyright  1988-2002. The Medical Letter, Inc. Phone: 1 ...
Cytomegalovirus immune globulin (CMVIG) for intravenous administration is now available in the USA on an investigational basis (FE Young and SL Nightingale, JAMA, 260:224, July 8, 1988) for prevention of cytomegalovirus (CMV) infection in CMV-seronegative renal transplant recipients who receive a kidney from a seropositive donor. CMVIG contains IgG antibodies from a pool of healthy donors with high titers of antibodies against CMV. The drug can be obtained from the Massachusetts Department of Public Health Biologic Laboratories (617-522-3700, extension 264) or the American Red Cross...
Med Lett Drugs Ther. 1988 Oct 21;30(777):100 |  Show IntroductionHide Introduction

Balloon Dilatation Of The Prostate

   
The Medical Letter on Drugs and Therapeutics • Jun 29, 1990  (Issue 821)
or omission. Copyright  1988-2002. The Medical Letter, Inc. Phone: 1-800-211-2769 Fax: 1-914-632-1733 WEB ...
To avoid the morbidity and occasional mortality of transurethral resection or open prostatectomy, some urologists are now using balloon dilatation of the prostatic urethra to treat benign prostatic hypertrophy.
Med Lett Drugs Ther. 1990 Jun 29;32(821):64 |  Show IntroductionHide Introduction

Gonadorelin For Induction Of Ovulation

   
The Medical Letter on Drugs and Therapeutics • Jul 27, 1990  (Issue 823)
or omission. Copyright  1988-2002. The Medical Letter, Inc. Phone: 1-800-211-2769 Fax: 1-914-632-1733 WEB ...
Gonadorelin (goe nad oh rell'; in) acetate (Lutrepulse - Ortho), a synthetic decapeptide identical in amino acid sequence to human gonadotropin-releasing hormone (GnRH), was recently approved by the US Food and Drug Administration for treatment of primary hypothalamic amenorrhea. Gonadorelin hydrochloride (Factrel) was previously available for diagnostic use (Medical Letter, 25:106, 1983). Analogs of GnRH have been used to treat endometriosis and advanced cancer of the prostate (Medical Letter, 27:71, 1985).
Med Lett Drugs Ther. 1990 Jul 27;32(823):70-1 |  Show IntroductionHide Introduction